Literature DB >> 11246687

Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome Measures in Rheumatology. Minimal Clinically Important Difference.

D E Beaton1, C Bombardier, J N Katz, J G Wright, G Wells, M Boers, V Strand, B Shea.   

Abstract

The purpose of this paper is to describe a classification system for studies of responsiveness that was designed to help organize these studies, and identify those with the potential to provide information on minimal clinically important difference (MCID). We developed a 3 dimensional cube into which studies of responsiveness can be categorized based on their evaluation of 3 attributes: 1. individual or group setting; 2. which scores are contrasted; and 3. the type of change or difference being assessed. We present and discuss examples of studies that fit into categories in the classification cube. This classification system helps to focus attention on whether the literature is able to provide information on the specific type of change a person is interested in. It reinforces that the ability of an instrument to detect a certain category of discrimination within the cube does not mean it will necessarily be responsive to another category. The cube has been shown here as a means to separate out studies that address important change. These studies can then be examined as the source of information on MCID.

Entities:  

Mesh:

Year:  2001        PMID: 11246687

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  59 in total

1.  Patients with rheumatoid arthritis in clinical care.

Authors:  J S Smolen; D Aletaha
Journal:  Ann Rheum Dis       Date:  2004-03       Impact factor: 19.103

2.  Clinical trials in orthopaedics research. Part III. Overcoming operational challenges in the design and conduct of randomized clinical trials in orthopaedic surgery.

Authors:  Elena Losina; James Wright; Jeffrey N Katz
Journal:  J Bone Joint Surg Am       Date:  2012-03-21       Impact factor: 5.284

Review 3.  Sample size determination for cost-effectiveness trials.

Authors:  Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

4.  Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus.

Authors:  Hermine I Brunner; Gloria C Higgins; Marisa S Klein-Gitelman; Sivia K Lapidus; Judyann C Olson; Karen Onel; Marilynn Punaro; Jun Ying; Edward H Giannini
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07       Impact factor: 4.794

5.  Clinically meaningful change estimates for the six-minute walk test and daily activity in individuals with chronic heart failure.

Authors:  Michael J Shoemaker; Amy B Curtis; Eric Vangsnes; Michael G Dickinson
Journal:  Cardiopulm Phys Ther J       Date:  2013-09

6.  Does roflumilast improve dyspnea in patients with chronic obstructive pulmonary disease? A meta-analysis.

Authors:  Lei Pan; Yong-Zhong Guo; Bo Zhang; Jun-Hong Yan
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

Review 7.  Science of assessment.

Authors:  N Bellamy
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

8.  Minimally important change determined by a visual method integrating an anchor-based and a distribution-based approach.

Authors:  Henrica C W de Vet; Raymond W J G Ostelo; Caroline B Terwee; Nicole van der Roer; Dirk L Knol; Heleen Beckerman; Maarten Boers; Lex M Bouter
Journal:  Qual Life Res       Date:  2006-10-11       Impact factor: 4.147

9.  DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists.

Authors:  Federico Navarro-Sarabia; Dolores Ruiz-Montesinos; Blanca Hernandez; Victoria Navarro-Compán; Sara Marsal; Mireia Barcelo; Eva Perez-Pampín; Juan J Gómez-Reino
Journal:  BMC Musculoskelet Disord       Date:  2009-07-23       Impact factor: 2.362

10.  Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes.

Authors:  Tom Stargardt; Linda Gonder-Frederick; Karl J Krobot; Charles M Alexander
Journal:  Health Qual Life Outcomes       Date:  2009-10-22       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.